Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK01 in Alzheimer's Disease
NCT04678453Phase 1Terminated
- Sponsor
- NKGen Biotech
- Start
- Jan 2021
- Primary completion
- Aug 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of troculeucel in Alzheimer's disease (AD) (4 cohorts), sponsored by NKGen Biotech. Primary endpoints: Incidence of Adverse Events at 6 months, Tolerability of SNK01 at 6 months and 1 more. Started Jan 2021; status: terminated.
02
Drugs
troculeucel
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04678453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678453.